Zimmer and Peacock are exhibiting at the Biomarkers and Immuno-Oncology World Congress 2017.
Biomarkers and Immuno-Oncology World Congress which is dedicated to all areas of biomarker research and development spanning the pharmaceutical and diagnostic pipelines. Zimmer and Peacock appreciate that the the promising developments in immuno-oncology over the past five years, much of the biomarker R&D has shifted to discovery and development of predictive biomarkers for immunotherapy patient stratification, understanding tumor mutational load and neoantigens in developing personalized immunotherapy approaches, using biomarker or mechanism data to choose rational combination immunotherapy, and applying immune profiling to predict response to immunotherapy. Zimmer and Peacock looks to partner with the developers of these technologies and through our services and products bring them to market.
